Chat message

In context

A single line often inverts meaning once you see what it answers, so neighbouring messages are always shown.

1. 2021-02-07 12:26 Kristian G. Andersen open
   Absolutely no effect preventing mild-moderate so I don't expect much ability to prevent severe either. But we'll see -this is very early data. It's just a shit vaccine - I'm sure the others won't see this bad a drop (and we have _some_ data on that) and will also prevent severe disease in many cases.
2. 2021-02-07 12:28 Andrew Rambaut open
   Leif is everywhere (and quite common on B.1.1.7)
3. 2021-02-07 12:29 Andrew Rambaut open
   When testing vaccines against B.1.351, are they using one with Leif and Karen?
4. 2021-02-07 12:29 Andrew Rambaut open
   Or the serum - do they know the genotype of the donor?
5. 2021-02-07 12:30 Robert F. Garry
   https://docs.google.com/document/d/17-2hi7-fNsjE44himeCkm1PoZ7_-ncvpxUlhShZzDCU/edit On another note - I just popped a *nearly clean draft* of a proposed Virological post about Cambodian, Thai and Japanese bat sarbecoviruses. It's actually pretty mild, but Alina etc. *do* get attention. I borrowed VERY heavily from this channel,so please let me know if you are co-authors or I can go solo...
6. 2021-02-07 12:30 Kristian G. Andersen open
   These are clinical trials - so wildtype
7. 2021-02-07 12:31 Kristian G. Andersen open
   What's critically important here - drop in efficacy, even bigger than drop observed in vitro
8. 2021-02-07 12:31 Kristian G. Andersen open
   (which is not surprising to me)
9. 2021-02-07 12:31 Andrew Rambaut open
   But do they know whether the infected cases are with a B.1.351 with Leif and/or Karen or one without

Full conversation →